LEADER 04476nam 2200517 450 001 9910137117303321 005 20170817211242.0 010 $a0-323-39566-X 035 $a(CKB)3710000000776375 035 $a(EBL)4621009 035 $a(OCoLC)956278046 035 $a(MiAaPQ)EBC4621009 035 $a(EXLCZ)993710000000776375 100 $a20160826h20152015 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 10$aManagement of Helicobacter pylori-related diseases /$fAkiko Shiotani, David Y. Graham 210 1$aPhiladelphia, Pennsylvania :$cElsevier,$d2015. 210 4$dİ2015 215 $a1 online resource (246 p.) 225 1 $aGastroenterology Clinics of North America,$x0889-8553 ;$vVolume 44, Number 3 300 $a"Clinics Review Articles." 311 $a0-323-39565-1 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aCover image; Title page; Table of Contents; Copyright Page; Contributors; Consulting Editor; Editors; Authors; Forthcoming Issues; Forthcoming Issues; Recent Issues; Foreword: Helicobacter pylori; Preface: Helicobacter pylori: New Thoughts and Practices; Diagnosis of Helicobacter pylori Infection in the Proton Pump Inhibitor Era; Key points; Introduction; Invasive tests; Serology; Summary: diagnosis of Helicobacter pylori infection in the proton pump inhibitors era; Practical Aspects in Choosing a Helicobacter pylori Therapy; Key points; Introduction; Choice of therapy; First-line regimens 327 $aRescue therapyProbiotics; Summary; How to Effectively Use Bismuth Quadruple Therapy; Key points; Background; Bismuth in the era of new concepts regarding pathogenesis and treatment of peptic ulcer; Bismuth quadruple therapy for H pylori eradication; The effect of metronidazole resistance as examined by meta-analysis; Calculation of the effectiveness of bismuth quadruple therapy; Adherence (compliance) with bismuth quadruple therapy; How to make bismuth quadruple therapy more acceptable; Doxycycline 327 $aExamination of outcome in regions where bismuth quadruple therapy frequently fails (eg, Turkey and Iran)Bismuth, tetracycline, amoxicillin, proton pump inhibitors quadruple therapy; Bismuth sequential therapies; Information needed to obtain generalizable results; Issues ripe for systematic study; Proton pump inhibitors dosage; Efficient study design; Recommendations; Is There a Role for Probiotics in Helicobacter pylori Therapy?; Key points; What probiotics are; Probiotics; Probiotics as adjuvant therapy for Helicobacter pylori eradication; Probiotics as cure for Helicobacter pylori infection 327 $aSummaryMolecular Approaches to Identify Helicobacter pylori Antimicrobial Resistance; Key points; Molecular determination of Helicobacter pylori resistance to macrolides; Molecular determination of Helicobacter pylori resistance to fluoroquinolones; Molecular determination of Helicobacter pylori resistance to tetracycline; Molecular determination of Helicobacter pylori resistance to other antibiotics; When Is Endoscopic Follow-up Appropriate After Helicobacter pylori Eradication Therapy?; Key points; Introduction; Helicobacter pylori eradication; Uninvestigated and nonulcer dyspepsia 327 $aPeptic ulcerPremalignant gastric lesions and early gastric cancer; Hereditary risk for gastric cancer; Mucosa-associated lymphoid tissue lymphoma; Summary; Gastric Cancer Risk in Patients with Helicobacter pylori Infection and Following Its Eradication; Key points; Introduction; Helicobacter pylori infection is the most important determinant of gastric cancer risk; Gastric cancer risk: epidemiologic trends; Gastric cancer risk: the assessment; Gastric cancer risk in eradicated patients; Summary; Molecular Pathogenesis of Helicobacter pylori-Related Gastric Cancer; Key points; Introduction 327 $aClassifications and characterizations of gastric cancer 410 0$aGastroenterology clinics of North America ;$vVolume 44, Number 3. 606 $aHelicobacter pylori 615 0$aHelicobacter pylori. 676 $a579.34 700 $aShiotani$b Akiko$01370376 702 $aGraham$b David Y. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910137117303321 996 $aManagement of Helicobacter pylori-related diseases$93398677 997 $aUNINA